Relationship between Endogenous Parathyroid Hormone and Bone Metabolism/Geometry in Female Patients Treated with Glucocorticoid

Abstract

Although the role of PTH (parathyroid hormone) has been debated in glucocorticoid (GC)-induced osteoporosis (GIO), clinical data about the relation of endogenous PTH to bone metabolism in patients treated with GC are still lacking. The present study was performed to examine the relationship of PTH to bone metabolic indices, bone mineral density (BMD), and bone geometry in 174 female patients treated with oral GC for more than 6 months. Dual-energy X-ray absorptiometry and peripheral quantitative computed tomography (pQCT) were employed for the assessment of BMD and bone geometry. No elevation of serum PTH levels was observed in patients treated with GC. Although serum levels of osteocalcin were not related to serum PTH levels, urinary levels of deoxypiridinoline were positively correlated. Serum PTH levels were negatively related to BMD at any site. In pQCT, serum PTH levels were negatively correlated to both trabecular and cortical volumetric BMD. As for bone morphometric indices, serum PTH levels were significantly related to endocortical circumferences, cortical thickness, and cortical area. Moreover, serum PTH levels were significantly higher in patients with vertebral fractures, compared with those without vertebral fractures in GC-treated patients. In the present study, serum PTH levels were related to the elevation of bone resorption marker, decreased BMD, cortical thinning, and an increase of vertebral fracture risk. The elevation of sensitivity to PTH in bone might play some role in the pathogenesis of GIO.

glucocorticoid - osteoporosis - parathyroid hormone

References

• 1 Rubin MR, Bilezikian JP. The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence.  J Clin Endocrinol Metab. 2002;  87 4033-4041
• 2 Mazziotti G, Angeli A, Bilezikian JP, Canalis E. Glucocorticoid-induced osteoporosis: an update.  Trends Endocrinol Metab. 2006;  17 144-149
• 3 Ross EJ, Linch DC. Cushing's syndrome-killing disease: discriminatory value of signs and symptoms aiding early diagnosis.  Lancet. 1982;  2 646-649
• 4 Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma.  N Engl J Med. 1983;  309 265-268
• 5 Bressot C, Meunier J, Lejeune E, Edouard C, Darby A. Histomorpho-metric profile, pathophysiology and reversibility of glucocorticoid-induced osteoporosis.  Metabolic Bone Dis Rel Res. 1979;  1 303-311
• 6 Chen Q, Kaji H, Iu MF, Nomura R, Sowa H, Yamauchi M, Tsukamoto T, Sugimoto T, Chihara K. Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects.  J Clin Endocrinol Metab. 2003;  88 2655-2658
• 7 Nakaoka D, Sugimoto T, Kaji H, Kanzawa M, Yano S, Yamauchi M, Sugishita T, Chihara K. Determinants of bone mineral density and spinal fracture risk in postmenopausal Japanese women.  Osteoporos Int. 2001;  12 548-554
• 8 Smith-Bindman R, Cummings SR, Steiger P, Genant HK. A comparison of morphometric definitions of vertebral fractures.  J Bone Miner Res. 1991;  6 25-34
• 9 Ruegsegger P, Durand E, Dambacher MA. Localization of regional forearm bone loss from high-resolution computed tomographic images.  Osteoporos Int. 1991;  1 76-80
• 10 Kaji H, Kosaka R, Yamauchi M, Kuno K, Chihara K, Sugimoto T. Effects of age, grip strength and smoking on forearm volumetric bone mineral density and bone geometry by peripheral quantitative computed tomography: comparisons between female and male.  Endocr J. 2005;  52 659-666
• 11 Kaji H, Iu MF, Naito J, Sugimoto T, Chihara K. A case of primary hyperparathyroidism with the marked change of bone mimeral density and bone morphometry after parathyroidectomy.  J Bone Miner Metab. 2006;  24 349-352
• 12 Shchiessl H, Ferretti JL, Tysarczyk-Niemeyer G. Noninvasive bone strength index as analysis by peripheral quantitative computed tomography (pQCT). In: Schonau E (ed). Pediatric osteology. New developments in diagnostics and therapy. Amsterdam: Elsevier 1996: 147-160
• 13 Lane NE, Lukert B. The science and therapy of glucocorticoid-induced bone loss.  Endoicrinol Metab Clin North Am. 1998;  27 465-483
• 14 Lund B, Storm TL, Melsen F, Mosekilde L, Andersen RB, Egmose C, Sorensen OH. Bone mineral loss, bone histomorphometry and vitamin D metabolism in patients with rheumatoid arthritis on long-term glucocorticoid treatment.  Clin Rheumatol. 1985;  4 143-149
• 15 Suzuki Y, Ishikawa Y, Saito E, Honma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidsm of patients under glucocorticoid therapy.  Metabolism. 1983;  32 151-156
• 16 Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH. Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration.  J Clin Invest. 1979;  64 655-665
• 17 Gennari C, Imbimbo B, Montagnani M, Bernini M, Nardi P, Avioli LV. Effects of prednisone and defrazacort on mineral metabolism and parathyroid hormone activity in humans.  Calcif Tissue Int. 1984;  36 245-252
• 18 Lukert BP, Adams JS. Calcium and phosphorus homeostasis in man. Effect of glucocorticoids.  Arch Intern Med. 1976;  136 1249-1253
• 19 Cosman F, Nieves J, Herbert J, Shen V, Lidsay R. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton.  J Bone Miner Res. 1994;  9 1097-1105
• 20 Paz-Pacheco E, El-haji Fuleihan G, Leboff MS. Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects.  J Bone Miner Res. 1995;  10 1713-1718
• 21 Kaji H, Tobimatsu T, Naito J, Iu MF, Yamauchi M, Sugimoto T, Chihara K. Body composition and vertebral fracture risk in female patients treated with glucocorticoid.  Osteoporos Int. 2006;  17 627-633
• 22 Hattersley AT, Meeran K, Burrin J, Hill P, Shiner R, Ibbertson HK. The effect of long- and short-term corticosteroids on plasma calcitonin and parathyroid hormone levels.  Calcif Tissue Int. 1994;  54 198-202
• 23 Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E. Corticosteroid-induced bone loss in men.  J Clin Endocrinol Metab. 1998;  83 801-806
• 24 Kaji H, Yamauchi M, Chihara K, Sugimoto T. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid -induced osteoporosis.  Endocr J. 2006;  53 27-34
• 25 Kaji H, Yamauchi M, Chihara K, Sugimoto T. The threshold of bone mineral density for vertebral fractures in female patients with primary hyperparathyroidism.  Eur J Endocrinol. 2005;  153 373-378
• 26 Kaji H, Nomura R, Yamauchi M, Chihara K, Sugimoto T. The usefulness of bone metabolic indices for the prediction of changes in bone mineral density after parathyroidectomy in patients with primary hyperparathyroidism.  Horm Metab Res. 2006;  38 411-416
• 27 Yamamoto I, Potts  Jr  JT, Segre GV. Glucocorticoid increase parathyroid hormone receptors in rat osteoblastic osteosarcoma cells (ROS 17/2).  J Bone Miner Res. 1988;  3 707-712
• 28 Urena P, Iida-Klein A, Juppner H, Kronenberg HM, Abou-Samra AB, Segre GV. Regulation of parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acid by glucocorticoids and PTH in ROS 17/2.8 and OK cells.  Endocrinology. 1994;  134 451-456
• 29 Majeska RJ, Nair BC, Rodan GA. Glucocorticoid regulation of alkaline phosphatase in the osteoblastic osteosarcoma cell line ROS 17/2.8.  Endocrinology. 1985;  116 170-179
• 30 Kaji H, Sugimoto T, Kanatani M, Nishiyama K, Chihara K. Dexamethasone stimulates osteoclast-like cell formation by directly acting on hemopoietic blast cells and enhances osteoclast-like cell formation stimulated by parathyroid hormone and prostaglandin E2.  J Bone Miner Res. 1997;  12 734-741
• 31 Conaway HH, Grigorie D, Lerner UH. Differential effects of glucocorticoids on bone resorption in neonatal mouose calvariae stimulated by peptide and steroid-like hormones.  J Endocrinol. 1997;  155 513-521
• 32 Bonadonna S, Burattin A, Nuzzo M, Bugari G, Rosei EA, Valle D, Iori N, Bilezikian JP, Veldhuis JD, Giustina A. Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects.  Eur J Endocrinol. 2005;  152 199-205
• 33 Lehman R, Wapniarz M, Kvasnicka HM, Baedeker S, Klein K, Allolio B. Reproducibility of bone density measurements of the distal radius using a high resolution special scanner for peripheral quantitative computed tomography (Single Energy PQCT).  Radiology. 1992;  32 177-181
• 34 Zanchetta J, Bogado C, Ferretti J, Wang O, Wilson M, Sato M, Gaich G, Dalsky G, Myers S. Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis.  J Bone Miner Res. 2003;  18 539-543
• 35 Hirano T, Burr DB, Cain RL, Hock JM. Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34).  Calcif Tissue Int. 2000;  66 456-460
• 36 Laan RFJM, Buijs WCAM, Erning TJTO, Lemmens JAM, Corstens FHM, Ruijs SHJ, Putte LBA, Riel PLCM. Differential effects of glucocorticoids on cortical appendicular and cortical vertebral bone mineral content.  Calcif Tissue Int. 1993;  52 5-9
• 37 Tsugeno H, Goto B, Fujita T, Okamoto M, Mifune T, Mitsunobu F, Ashida K, Hosaki Y, Tsuji T, Tanizaki Y. Oral glucocorticoid-induced fall in cortical bone volume and density in postmenopausal asthmatic patients.  Osteoporos Int. 2001;  12 266-270
• 38 Tsugeno H, Fujita T, Goto B, Sugishita T, Hosaki Y, Ashida K, Mitsunobu F, Tanizaki Y, Shiratori Y. Vertebral fracture and cortical bone changes in corticosteroid-induced osteoporosis.  Osteoporos Int. 2002;  13 650-656

Correspondence